Warner, Christopher J. A. et al. published their research in Tetrahedron in 2019 |CAS: 168297-86-7

The Article related to phosphine oxide hydroxy chiral preparation organocatalyst asym hydrosilylation ketimine, chiral aromatic amine preparation asym hydrosilylation organocatalyst phosphine oxide, diphosphine oxide phosphorus chiral preparation organocatalyst asym hydrosilylation ketimine and other aspects.Synthetic Route of 168297-86-7

On December 13, 2019, Warner, Christopher J. A.; Berry, Sian S.; Jones, Simon published an article.Synthetic Route of 168297-86-7 The title of the article was Evaluation of bifunctional chiral phosphine oxide catalysts for the asymmetric hydrosilylation of ketimines. And the article contained the following:

A series of hydroxy-functionalized bifunctional phosphine oxides and diphosphine dioxides have been prepared and evaluated as catalysts for the trichlorosilane mediated asym. hydrosilylation of ketimines. Bis-Phosphine oxides, hydroxy-phosphine oxides, and biaryl phosphine oxides all demonstrated good catalytic activity, but poor to moderate enantioselectivity. A bis-P-chiral phosphine oxide (R,R)-Ph(2-MeOC6H4)P(CH2)6PPh(2-MeOC6H4) (32) displayed the highest enantioselectivity of 60%. The experimental process involved the reaction of (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one(cas: 168297-86-7).Synthetic Route of 168297-86-7

The Article related to phosphine oxide hydroxy chiral preparation organocatalyst asym hydrosilylation ketimine, chiral aromatic amine preparation asym hydrosilylation organocatalyst phosphine oxide, diphosphine oxide phosphorus chiral preparation organocatalyst asym hydrosilylation ketimine and other aspects.Synthetic Route of 168297-86-7

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

 

Pallavicini, Marco et al. published their research in Tetrahedron: Asymmetry in 2004 |CAS: 97859-49-9

The Article related to hydroxymethyl oxazolidinone resolution preferential crystallization, phase diagram hydroxymethyl oxazolidinone resolution preferential crystallization, differential scanning calorimetry hydroxymethyl oxazolidinone resolution preferential crystallization and other aspects.Reference of (R)-5-(Hydroxymethyl)oxazolidin-2-one

On May 24, 2004, Pallavicini, Marco; Bolchi, Cristiano; Di Pumpo, Raffaella; Fumagalli, Laura; Moroni, Barbara; Valoti, Ermanno; Demartin, Francesco published an article.Reference of (R)-5-(Hydroxymethyl)oxazolidin-2-one The title of the article was Resolution of 5-hydroxymethyl-2-oxazolidinone by preferential crystallization and investigations on the nature of the racemates of some 2-oxazolidinone derivatives. And the article contained the following:

After ascertaining its conglomerate nature by DSC and solid-state IR analyses, 5-hydroxymethyl-2-oxazolidinone (I), whose enantiomers are very important synthons, was efficiently resolved without chiral auxiliaries by preferential crystallization from a supersaturated isopropanolic solution of (±)-I, slightly enriched in one enantiomer (3.7% ee). Favorable conditions to the entrainment were defined utilizing a previously constructed ternary phase diagram of (R)-I, (S)-I, and 2-propanol. Furthermore, the investigations were extended to other chiral 2-oxazolidinones with a functionalized Me at the 5- or 4-position finding that 5-[(tosyloxy)methyl]-2-oxazolidinone is a racemic compound, whereas just the corresponding mesylate is a conglomerate as the parent alc. I. Interestingly, 4-(hydroxymethyl)-2-oxazolidinone proved to be a racemic compound in contrast with its positional isomer I demonstrating how a relatively fine variation in the mol. structure can unpredictably influence the crystalline nature of the racemate. The X-ray structure determination carried out on (S)-(+)-I, (±)-4-(hydroxymethyl)-2-oxazolidinone and (R)-(+)-4-(hydroxymethyl)-2-oxazolidinone enlightened the importance of the hydrogen bond in determining different supramol. assembling in the two homochiral compounds with respect to the racemic one and allowed a correlation with the stability of the crystal to be made. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Reference of (R)-5-(Hydroxymethyl)oxazolidin-2-one

The Article related to hydroxymethyl oxazolidinone resolution preferential crystallization, phase diagram hydroxymethyl oxazolidinone resolution preferential crystallization, differential scanning calorimetry hydroxymethyl oxazolidinone resolution preferential crystallization and other aspects.Reference of (R)-5-(Hydroxymethyl)oxazolidin-2-one

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

 

Guo, Bin et al. published their research in Journal of Medicinal Chemistry in 2013 |CAS: 97859-49-9

The Article related to oxazolooxazinone pyridyl substituted preparation solubility driven optimization antibacterial activity, antibacterial activity sar gram pos bacteria oxazolooxazinone herg inhibition, sodium phosphate prodrug solubility pharmacokinetic and other aspects.Application In Synthesis of (R)-5-(Hydroxymethyl)oxazolidin-2-one

On March 28, 2013, Guo, Bin; Fan, Houxing; Xin, Qisheng; Chu, Wenjing; Wang, Hui; Huang, Yanqin; Chen, Xiaoyan; Yang, Yushe published an article.Application In Synthesis of (R)-5-(Hydroxymethyl)oxazolidin-2-one The title of the article was Solubility-Driven Optimization of (Pyridin-3-yl) Benzoxazinyl-oxazolidinones Leading to a Promising Antibacterial Agent. And the article contained the following:

The solubility-driven structural modification of substituted (pyridin-3-yl)-containing hydrobenzo[b]oxazolo[3,4-d][1,4]oxazinones is described, which resulted in the development of a new series of benzo[b]oxazolo[3,4-d][1,4]oxazinone analogs with high antibacterial activity against Gram-pos. pathogens, including that against linezolid-resistant strains, and low hERG inhibition. With regard to structure-activity relationship (SAR) trends among the various substituents on the pyridyl ring, relatively small and nonbasic substituents were preferable to sterically demanding or basic substituents. Oxazolidinone ring substitution on the pyridyl ring generated analogs with antibacterial activity superior to imidazolidinone ring. Solubility was enhanced by the incorporation of polar groups, especially when compounds were converted to their prodrugs. Among the prodrugs, compound I exhibited excellent solubility and a good pharmacokinetic profile. In a MRSA systemic infection model, compound I displayed an ED50 = 5.00 mg/kg, a potency that is 2-fold better than that of linezolid. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Application In Synthesis of (R)-5-(Hydroxymethyl)oxazolidin-2-one

The Article related to oxazolooxazinone pyridyl substituted preparation solubility driven optimization antibacterial activity, antibacterial activity sar gram pos bacteria oxazolooxazinone herg inhibition, sodium phosphate prodrug solubility pharmacokinetic and other aspects.Application In Synthesis of (R)-5-(Hydroxymethyl)oxazolidin-2-one

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

 

Sciotti, Richard J. et al. published their patent in 2002 |CAS: 97859-49-9

The Article related to oxazolidinone chemotherapeutic agent asym synthesis chemotherapy toxicity treatment method, psoriasis treatment method oxazolidinone chemotherapeutic agent asym synthesis, arthritis treatment method oxazolidinone chemotherapeutic agent asym synthesis, bacterial infection treatment method oxazolidinone chemotherapeutic agent asym synthesis and other aspects.HPLC of Formula: 97859-49-9

On March 7, 2002, Sciotti, Richard J.; Djuric, Steven W.; Pliushchev, Marina published a patent.HPLC of Formula: 97859-49-9 The title of the patent was Preparation of oxazolidinone chemotherapeutic agents. And the patent contained the following:

Compounds of the formula I [A = Ph, substituted five-membered aromatic ring containing 1 or 2 atoms selected from N, O, and S and the remaining atoms are carbon, or substituted 6-membered aromatic ring containing 1 or 2 nitrogen atoms and the remaining atoms are carbon; R1, R2 = independently H, alkyl, cycloalkyl, hydroxy, amino, halo, haloalkyl, and perfluoroalkyl; R3 = optionally substituted alkyl, alkanoyl, carboxamido, cycloalkyl, cyclothioalkoxy, etc.; R4 = substituted N, O, or S] or therapeutically acceptable salts or prodrugs thereof were prepared Thus, Me 4-((4-((5S)-5-((acetylamino)methyl)-2-oxo-1,3-oxazolidin-3-yl)-2-fluorophenyl)ethynyl)benzoate (II) was synthesized in 6 steps from (5R)-5-(hydroxymethyl)-1,3-oxazolidin-2-one (III). Oxazolidinones of formula I are useful for treating bacterial infections, psoriasis, arthritis, and toxicity due to chemotherapy. Preparation of the compounds, compositions containing the compounds, and treatment of diseases using the compounds are disclosed. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).HPLC of Formula: 97859-49-9

The Article related to oxazolidinone chemotherapeutic agent asym synthesis chemotherapy toxicity treatment method, psoriasis treatment method oxazolidinone chemotherapeutic agent asym synthesis, arthritis treatment method oxazolidinone chemotherapeutic agent asym synthesis, bacterial infection treatment method oxazolidinone chemotherapeutic agent asym synthesis and other aspects.HPLC of Formula: 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

 

Brun, Elodie et al. published their research in Journal of Organic Chemistry in 2016 |CAS: 168297-86-7

The Article related to filipin iii acyclic carbon skeleton preparation convergent strategy, hexanal synthon filipin iii acyclic carbon skeleton, successive heck coupling reaction filipin iii synthesis, aldolization evans syn anti filipin iii synthesis, enantioselective allylation filipin iii synthesis, diastereoselective allylation filipin iii synthesis and other aspects.Electric Literature of 168297-86-7

On September 16, 2016, Brun, Elodie; Bellosta, Veronique; Cossy, Janine published an article.Electric Literature of 168297-86-7 The title of the article was Synthesis of the Acyclic Carbon Skeleton of Filipin III. And the article contained the following:

The synthesis of the carbon skeleton I of filipin III (II), a polyenic macrolactone possessing 11 stereogenic centers, has been achieved using a convergent strategy with a longest linear sequence of 19 steps starting from hexanal. The construction of the polyene has been realized by using two successive Heck couplings as the key steps. The control of the stereogenic centers of the polyol fragment has been performed by utilizing an Evans aldolization, a 1,3-syn aldolization, enantio- and diastereoselective allylations, an hemiacetalization/oxa-Michael sequence and a 1,3-syn reduction The polyol and polyenic fragments have been coupled using a 1,5-anti diastereoselective aldolization followed by a 1,3-anti reduction The experimental process involved the reaction of (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one(cas: 168297-86-7).Electric Literature of 168297-86-7

The Article related to filipin iii acyclic carbon skeleton preparation convergent strategy, hexanal synthon filipin iii acyclic carbon skeleton, successive heck coupling reaction filipin iii synthesis, aldolization evans syn anti filipin iii synthesis, enantioselective allylation filipin iii synthesis, diastereoselective allylation filipin iii synthesis and other aspects.Electric Literature of 168297-86-7

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

 

Sagawa, Naoya et al. published their research in Organic Letters in 2017 |CAS: 168297-86-7

The Article related to remote asym induction acetate vinylketene silyl nitrogen oxygen acetal, crystal structure oxazolidinone vinylketene silyl acetal hydroxyoxoalkenyl preparation asym, mol structure oxazolidinone vinylketene silyl acetal hydroxyoxoalkenyl preparation asym, aldehyde asym induction remote mukaiyama aldol vinylketene silyl acetal and other aspects.Computed Properties of 168297-86-7

On January 6, 2017, Sagawa, Naoya; Sato, Haruka; Hosokawa, Seijiro published an article.Computed Properties of 168297-86-7 The title of the article was Remote Asymmetric Induction Using Acetate-Type Vinylketene Silyl N,O-Acetals. And the article contained the following:

Remote asym. induction by the vinylogous Mukaiyama aldol reaction using the acetate-type vinylketene silyl N,O-acetal possessing a chiral auxiliary was achieved. The silyl N,O-acetal derived from crotonate and L-valine afforded the O-silylated 5R- and 5S-adducts selectively by treatment with SnCl4 and BF3·OEt2, resp. The SnCl4-mediated isomerization of silyl dienol ether was found, and the resulting major isomer showed high reactivity to give γ-adduct in high stereoselectivity. The experimental process involved the reaction of (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one(cas: 168297-86-7).Computed Properties of 168297-86-7

The Article related to remote asym induction acetate vinylketene silyl nitrogen oxygen acetal, crystal structure oxazolidinone vinylketene silyl acetal hydroxyoxoalkenyl preparation asym, mol structure oxazolidinone vinylketene silyl acetal hydroxyoxoalkenyl preparation asym, aldehyde asym induction remote mukaiyama aldol vinylketene silyl acetal and other aspects.Computed Properties of 168297-86-7

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

 

Sebhat, Iyassu et al. published their patent in 2020 |CAS: 168297-86-7

The Article related to acyloxyphenylcyclopropylpropanoic acid preparation gpr40 agonist, metabolic disorder type 2 diabetes treatment gpr40 agonist preparation, hyperglycemia metabolic syndrome obesity treatment gpr40 agonist preparation, hypercholesterolemia nonalcoholic steatohepatitis hypertension treatment gpr40 agonist preparation and other aspects.Formula: C8H15NO2

On December 3, 2020, Sebhat, Iyassu; He, Shuwen published a patent.Formula: C8H15NO2 The title of the patent was Preparation of 3-cyclopropyl-3-(3-acyloxyphenyl)propanoic acid derivatives as Gpr40 agonists. And the patent contained the following:

The compounds represented by formula I [Z = C(O)OH, C(O)OR5, C(O)NHR6, C(O)NHS(O)2R5, S(O)2NHC(O)R5, P(O)(R5)OR6, P(O)(OR6)2, S(O)2OR6; or Z = (un)substituted 4- or 5-membered heterocycle; R5 = each (un)substituted C1-6 alkyl, C3-6 cycloalkyl, Ph, or phenyl-C1-6 alkyl; R6 = hydrogen or each (un)substituted C1-6 alkyl, C3-6 cycloalkyl, Ph, or phenyl-C1-6 alkyl; R1, R2, R3, R4 = each independently hydrogen, halogen, OH, or each (un)substituted C1-6 alkyloxy, C1-6 alkyl, C3-6 cycloalkyl, or 3- to 6-membered heterocycloalkyl; Y1, Y2, Y3, or Y4 = each independently N, CH, or CRY; each RY = independently halogen, cyano, OH, NH2, or each (un)substituted C1-6 alkoxy, NH-(C1-6 alkyl), N-(C1-6 alkyl)2, C1-6 alkyl, C3-6 cycloalkyl, or 3- to 6-membered heterocycloalkyl; L1 = *-OC(O)-, or *-C(O)O-, wherein * represents the connection to Ring B; Ring B = each (un)substituted arylene, heteroarylene, C3-10 cycloalkylene, or 3- to 10-membered heterocycloalkylene; L2 = a bond or each (un)substituted C1-6 alkylene, or -(C1-6 alkylene)-O-] or pharmaceutically acceptable salts, solvates, stereoisomers, or prodrugs thereof are prepared The compounds I are gut-restricted compounds and full or partial G protein-coupled receptor 40 (GPR40) agonists and useful for the treatment of conditions or disorders involving the gut-brain axis. The conditions or disorder is (1) a metabolic disorder such as type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, nonalcoholic steatohepatitis, or hypertension or (2) a nutritional disorder such as short bowel syndrome, intestinal failure, or intestinal insufficiency. Thus, a solution of 0.28 g 3-[(diisopropylamino)methyl]-4-(5-fluoro-2-methoxypyridin-4-yl)benzoic acid and 0.13 g Me (S)-3-cyclopropyl-3-(3-hydroxyphenyl)propanoate in 3 mL CH2Cl2 was treated with 35 mg 4-dimethylaminopyridine and 0.18 g DCC and stirred at 25° for 16 h to give, after workup and purification using preparative TLC, (S)-3-cyclopropyl-3-[3-[[3-[(diisopropylamino)methyl]-4-(5-fluoro-2-methoxypyridin-4-yl)benzoyl]oxy]phenyl]propanoic acid (II). II showed an agonist activity with EC50 of ≤10 nM in a human GPR40 assay. The experimental process involved the reaction of (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one(cas: 168297-86-7).Formula: C8H15NO2

The Article related to acyloxyphenylcyclopropylpropanoic acid preparation gpr40 agonist, metabolic disorder type 2 diabetes treatment gpr40 agonist preparation, hyperglycemia metabolic syndrome obesity treatment gpr40 agonist preparation, hypercholesterolemia nonalcoholic steatohepatitis hypertension treatment gpr40 agonist preparation and other aspects.Formula: C8H15NO2

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem